Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ahmed Elzoghby, Ph.D.

Profile Picture

Brigham and Women's Hospital, Harvard Medical SchoolPostdoctoral Fellow07/2022Biomedical Engineering (Immunoengineering)
Cancer Nanotechnology Research Laboratory (CNRL) PI12/2017Pharmaceutical Sciences (Drug Delivery)
Faculty of Pharmacy, Alexandria University Ph.D.10/2012Pharmaceutical Sciences (Drug Delivery)
Faculty of Pharmacy, Alexandria UniversityM.Sc.09/2009Pharmaceutical Sciences (Drug Delivery)
Faculty of Pharmacy, Alexandria UniversityB.Sc.06/2003Pharmaceutical Sciences
Fulbright Visiting Scholar Award
Highly Cited Researcher Award 2021
Highly Cited Researcher Award 2022

My research focuses on immunoengineering of tumor microenvironment (TME) to overcome the resistance to cancer immunotherapy. More particularly, I am engineering innovative nanomedicines to disrupt the vicious crosstalk between cancer cells and stromal cancer associated fibroblasts (CAFs) via modulating the release and cargo of tumoral and stromal exosomes.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. 2022A015398 (Ahmed Elzoghby) Nov 1, 2022 - Oct 31, 2023
    BRIght Futures Prize 2022, Brigham Research Institute (BRI)
    Genetically Engineered Fibroblasts as In Situ Factory of Cytolytic Exosomes
    Role: Principal Investigator
  2. DNPI15053 (Adnan Bekhit) Apr 3, 2017 - Apr 3, 2019
    Science& Technology Development Fund (STDF)
    Synthesis and Evaluation of Drug-Polymer Conjugate Nano-Micelles for Targeted Brain Tumor Therapy
    Role: Co-Principal Investigator
  3. DNPI5731 (Ahmed Elzoghby) Apr 20, 2013 - Apr 20, 2016
    Science & Technology Development Fund (STDF)
    Inhalable Anti-Cancer Drug-Loaded Nanocomposites for Enhanced Lung Cancer Targeting
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Abdelgalil RM, Elmorshedy YM, Elkhodairy KA, Teleb M, Bekhit AA, Khattab SN, Elzoghby AO. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy. Nanomedicine (Lond). 2022 Sep; 17(22):1721-1745. PMID: 36621872.
    Citations:    Fields:    
  2. Elzoghby AO, Ferrone CR, Ferrone S, Nasr ML. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discov Today. 2023 Jan; 28(1):103434. PMID: 36368630.
    Citations:    Fields:    Translation:Humans
  3. Salah M, Sallam MA, Abdelmoneem MA, Teleb M, Elkhodairy KA, Bekhit AA, Khafaga AF, Noreldin AE, Elzoghby AO, Khattab SN. Sequential Delivery of Novel Triple Drug Combination via Crosslinked Alginate/Lactoferrin Nanohybrids for Enhanced Breast Cancer Treatment. Pharmaceutics. 2022 Nov 08; 14(11). PMID: 36365222; PMCID: PMC9693489.
  4. Atallah MA, Sallam MA, Abdelmoneem MA, Teleb M, Elkhodairy KA, Bekhit AA, Khafaga AF, Noreldin AE, Elzoghby AO, Khattab SN. Green self-assembled lactoferrin carboxymethyl cellulose nanogels for synergistic chemo/herbal breast cancer therapy. Colloids Surf B Biointerfaces. 2022 Sep; 217:112657. PMID: 35803031.
    Citations:    Fields:    
  5. Mokhtar S, Khattab SN, Elkhodairy KA, Teleb M, Bekhit AA, Elzoghby AO, Sallam MA. Methotrexate-Lactoferrin Targeted Exemestane Cubosomes for Synergistic Breast Cancer Therapy. Front Chem. 2022; 10:847573. PMID: 35392419; PMCID: PMC8980280.
    Citations: 1     
  6. Hafez DA, Hassanin IA, Teleb M, Khattab SN, Elkhodairy KA, Elzoghby AO. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy. Nanomedicine (Lond). 2021 10; 16(25):2305-2325. PMID: 34551585.
    Citations: 1     Fields:    Translation:Humans
  7. Anwar DM, El-Sayed M, Reda A, Fang JY, Khattab SN, Elzoghby AO. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes. Expert Opin Drug Deliv. 2021 11; 18(11):1609-1625. PMID: 34254868.
    Citations: 3     Fields:    Translation:Humans
  8. Khafaga AF, Shamma RN, Abdeen A, Barakat AM, Noreldin AE, Elzoghby AO, Sallam MA. Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies. Nanomedicine (Lond). 2021 08; 16(19):1691-1712. PMID: 34264123.
    Citations:    Fields:    Translation:Humans
  9. AbdElhamid AS, Zayed DG, Heikal L, Khattab SN, Mady OY, El-Gizawy SA, Elzoghby AO. Recent advances in polymer shell oily-core nanocapsules for drug-delivery applications. Nanomedicine (Lond). 2021 08; 16(18):1613-1625. PMID: 34189946.
    Citations:    Fields:    
  10. Metawea ORM, Abdelmoneem MA, Haiba NS, Khalil HH, Teleb M, Elzoghby AO, Khafaga AF, Noreldin AE, Albericio F, Khattab SN. A novel 'smart' PNIPAM-based copolymer for breast cancer targeted therapy: Synthesis, and characterization of dual pH/temperature-responsive lactoferrin-targeted PNIPAM-co-AA. Colloids Surf B Biointerfaces. 2021 Jun; 202:111694. PMID: 33740633.
    Citations: 6     Fields:    Translation:Animals
  11. Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020; 3(4):930-946. PMID: 35582218; PMCID: PMC8992568.
    Citations: 1     
  12. Rofeal MG, Elzoghby AO, Helmy MW, Khalil R, Khairy H, Omar S. Dual Therapeutic Targeting of Lung Infection and Carcinoma Using Lactoferrin-Based Green Nanomedicine. ACS Biomater Sci Eng. 2020 10 12; 6(10):5685-5699. PMID: 33320553.
    Citations: 2     Fields:    Translation:Humans
  13. Elzoghby AO, Abdelmoneem MA, Hassanin IA, Abd Elwakil MM, Elnaggar MA, Mokhtar S, Fang JY, Elkhodairy KA. Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand. Biomaterials. 2020 12; 263:120355. PMID: 32932142; PMCID: PMC7480805.
    Citations: 13     Fields:    
  14. Hassanin IA, Elzoghby AO. Self-assembled non-covalent protein-drug nanoparticles: an emerging delivery platform for anti-cancer drugs. Expert Opin Drug Deliv. 2020 10; 17(10):1437-1458. PMID: 32820954.
    Citations: 4     Fields:    Translation:Humans
  15. Abdelmoneem MA, Abd Elwakil MM, Khattab SN, Helmy MW, Bekhit AA, Abdulkader MA, Zaky A, Teleb M, Elkhodairy KA, Albericio F, Elzoghby AO. Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-?B inhibitor celastrol. Mater Sci Eng C Mater Biol Appl. 2021 Jan; 118:111422. PMID: 33255023.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  16. Elhasany KA, Khattab SN, Bekhit AA, Ragab DM, Abdulkader MA, Zaky A, Helmy MW, Ashour HMA, Teleb M, Haiba NS, Elzoghby AO. Combination of magnetic targeting with synergistic inhibition of NF-?B and glutathione via micellar drug nanomedicine enhances its anti-tumor efficacy. Eur J Pharm Biopharm. 2020 Oct; 155:162-176. PMID: 32818610.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  17. Gaber M, Elhasany KA, Sabra S, Helmy MW, Fang JY, Khattab SN, Bekhit AA, Teleb M, Elkodairy KA, Elzoghby AO. Co-Administration of Tretinoin Enhances the Anti-Cancer Efficacy of Etoposide via Tumor-Targeted Green Nano-Micelles. Colloids Surf B Biointerfaces. 2020 Apr 25; 192:110997. PMID: 32361378.
    Citations: 5     Fields:    
  18. Kamel NM, Samaha MW, Elzoghby AO, El-Kimary EI. Sensitive Inexpensive HPLC Determination of Novel Anticancer Combination in Nanoparticles and Rat Plasma: Pharmacokinetic Application. J Chromatogr Sci. 2020 Apr 23; 58(4):334-345. PMID: 32043118.
    Citations: 1     Fields:    Translation:Animals
  19. Nafee N, Gaber DM, Elzoghby AO, Helmy MW, Abdallah OY. Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles. Pharm Res. 2020 Apr 14; 37(4):82. PMID: 32291520.
    Citations: 2     Fields:    Translation:HumansCells
  20. Yu HP, Liu FC, Umoro A, Lin ZC, Elzoghby AO, Hwang TL, Fang JY. Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency. J Nanobiotechnology. 2020 Jan 31; 18(1):25. PMID: 32005196; PMCID: PMC6995149.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  21. Abdelaziz HM, Elzoghby AO, Helmy MW, Abdelfattah EA, Fang JY, Samaha MW, Freag MS. Inhalable Lactoferrin/Chondroitin-Functionalized Monoolein Nanocomposites for Localized Lung Cancer Targeting. ACS Biomater Sci Eng. 2020 02 10; 6(2):1030-1042. PMID: 33464839.
    Citations: 4     Fields:    Translation:Animals
  22. Hafez DA, Elkhodairy KA, Teleb M, Elzoghby AO. Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy. Expert Opin Drug Deliv. 2020 03; 17(3):279-285. PMID: 31997666.
    Citations: 2     Fields:    
  23. Ali OM, Bekhit AA, Khattab SN, Helmy MW, Abdel-Ghany YS, Teleb M, Elzoghby AO. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy. Colloids Surf B Biointerfaces. 2020 Apr; 188:110824. PMID: 32023511.
    Citations: 10     Fields:    Translation:HumansCells
  24. Kamel NM, Helmy MW, Samaha MW, Ragab D, Elzoghby AO. Multicompartmental lipid-protein nanohybrids for combined tretinoin/herbal lung cancer therapy. Nanomedicine (Lond). 2019 09; 14(18):2461-2479. PMID: 31456481.
    Citations:    Fields:    Translation:HumansAnimalsCells
  25. Gaber M, Hany M, Mokhtar S, Helmy MW, Elkodairy KA, Elzoghby AO. Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2019 Dec; 105:110099. PMID: 31546395.
    Citations: 6     Fields:    Translation:HumansCells
  26. Abdelmoneem MA, Elnaggar MA, Hammady RS, Kamel SM, Helmy MW, Abdulkader MA, Zaky A, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma. ACS Appl Mater Interfaces. 2019 Jul 31; 11(30):26731-26744. PMID: 31268657.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  27. Lin CY, Hsu CY, Elzoghby AO, Alalaiwe A, Hwang TL, Fang JY. Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomater. 2019 05; 90:350-361. PMID: 30951898.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  28. Kamel NM, Helmy MW, Abdelfattah EZ, Khattab SN, Ragab D, Samaha MW, Fang JY, Elzoghby AO. Inhalable Dual-Targeted Hybrid Lipid Nanocore-Protein Shell Composites for Combined Delivery of Genistein and All-Trans Retinoic Acid to Lung Cancer Cells. ACS Biomater Sci Eng. 2020 01 13; 6(1):71-87. PMID: 33463208.
    Citations: 3     Fields:    Translation:Animals
  29. Elzoghby AO. Pharmaceutical nanotechnology in Egypt: diverse applications and promising outcomes. Nanomedicine (Lond). 2019 03; 14(6):649-653. PMID: 30693819.
    Citations: 1     Fields:    Translation:HumansCells
  30. Zayed DG, Ebrahim SM, Helmy MW, Khattab SN, Bahey-El-Din M, Fang JY, Elkhodairy KA, Elzoghby AO. Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids: covalent coupling and phospholipid complexation approaches. J Nanobiotechnology. 2019 Jan 19; 17(1):7. PMID: 30660179; PMCID: PMC6339697.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  31. Zayed DG, AbdElhamid AS, Freag MS, Elzoghby AO. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging. Nanomedicine (Lond). 2019 02; 14(3):225-228. PMID: 30652951.
    Citations: 5     Fields:    Translation:HumansAnimals
  32. Abdelaziz HM, Elzoghby AO, Helmy MW, Samaha MW, Fang JY, Freag MS. Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells. Int J Nanomedicine. 2019; 14:499-517. PMID: 30666110; PMCID: PMC6333390.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  33. Sabra SA, Sheweita SA, Haroun M, Ragab D, Eldemellawy MA, Xia Y, Goodale D, Allan AL, Elzoghby AO, Rohani S. Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells. J Pharm Sci. 2019 05; 108(5):1713-1725. PMID: 30528944.
    Citations: 9     Fields:    Translation:HumansCells
  34. Elzoghby AO, Freag MS. Toward improving drug delivery research in Egypt: Cancer Nanotechnology Research Laboratory (CNRL) as a role model. Drug Discov Today. 2019 02; 24(2):361-363. PMID: 30439448.
    Citations:    Fields:    Translation:Animals
  35. Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine (Lond). 2018 10; 13(19):2377-2395. PMID: 30346255.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  36. AbdElhamid AS, Zayed DG, Helmy MW, Ebrahim SM, Bahey-El-Din M, Zein-El-Dein EA, El-Gizawy SA, Elzoghby AO. Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine (Lond). 2018 10; 13(20):2637-2656. PMID: 30338705.
    Citations: 10     Fields:    Translation:HumansCells
  37. Gaber M, Mabrouk MT, Freag MS, Khiste SK, Fang JY, Elkhodairy KA, Elzoghby AO. Protein-polysaccharide nanohybrids: Hybridization techniques and drug delivery applications. Eur J Pharm Biopharm. 2018 Dec; 133:42-62. PMID: 30300719.
    Citations: 7     Fields:    Translation:HumansAnimals
  38. Elgohary MM, Helmy MW, Mortada SM, Elzoghby AO. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Nanomedicine (Lond). 2018 09; 13(17):2221-2224. PMID: 30265215.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  39. Abd Elwakil MM, Mabrouk MT, Helmy MW, Abdelfattah EA, Khiste SK, Elkhodairy KA, Elzoghby AO. Inhalable lactoferrin-chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma. Nanomedicine (Lond). 2018 08; 13(16):2015-2035. PMID: 30191764.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  40. Anwar DM, Khattab SN, Helmy MW, Kamal MK, Bekhit AA, Elkhodairy KA, Elzoghby AO. Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma. Bioconjug Chem. 2018 09 19; 29(9):3026-3041. PMID: 30110148.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  41. Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J Control Release. 2018 10 10; 287:78-93. PMID: 30138716.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  42. El-Lakany SA, Elgindy NA, Helmy MW, Abu-Serie MM, Elzoghby AO. Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer. Expert Opin Drug Deliv. 2018 09; 15(9):835-850. PMID: 30067113.
    Citations: 8     Fields:    Translation:HumansAnimals
  43. Elgohary MM, Helmy MW, Abdelfattah EA, Ragab DM, Mortada SM, Fang JY, Elzoghby AO. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy. J Control Release. 2018 09 10; 285:230-243. PMID: 30009892.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  44. Chen CH, Chen CJ, Elzoghby AO, Yeh TS, Fang JY. Self-assembly and directed assembly of lipid nanocarriers for prevention of liver fibrosis in obese rats: a comparison with the therapy of bariatric surgery. Nanomedicine (Lond). 2018 07; 13(13):1551-1566. PMID: 29998778.
    Citations: 3     Fields:    Translation:HumansAnimals
  45. AbdElhamid AS, Helmy MW, Ebrahim SM, Bahey-El-Din M, Zayed DG, Zein El Dein EA, El-Gizawy SA, Elzoghby AO. Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. Nanomedicine (Lond). 2018 Jul 01; 13(14):1707-1730. PMID: 30073915.
    Citations: 1     Fields:    
  46. El-Far SW, Helmy MW, Khattab SN, Bekhit AA, Hussein AA, Elzoghby AO. Folate conjugated vs PEGylated phytosomal casein nanocarriers for codelivery of fungal- and herbal-derived anticancer drugs. Nanomedicine (Lond). 2018 06; 13(12):1463-1480. PMID: 29957120.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  47. Kabary DM, Helmy MW, Abdelfattah EA, Fang JY, Elkhodairy KA, Elzoghby AO. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma. Eur J Pharm Biopharm. 2018 Sep; 130:152-164. PMID: 29964122.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  48. Sallam MA, Elzoghby AO. Flutamide-Loaded Zein Nanocapsule Hydrogel, a Promising Dermal Delivery System for Pilosebaceous Unit Disorders. AAPS PharmSciTech. 2018 Jul; 19(5):2370-2382. PMID: 29882189.
    Citations:    Fields:    Translation:Animals
  49. Kabary DM, Helmy MW, Elkhodairy KA, Fang JY, Elzoghby AO. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B Biointerfaces. 2018 09 01; 169:183-194. PMID: 29775813.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  50. Sabra SA, Elzoghby AO, Sheweita SA, Haroun M, Helmy MW, Eldemellawy MA, Xia Y, Goodale D, Allan AL, Rohani S. Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. Eur J Pharm Biopharm. 2018 Jul; 128:156-169. PMID: 29689288.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  51. Liu FC, Yu HP, Lin CY, Elzoghby AO, Hwang TL, Fang JY. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J Nanobiotechnology. 2018 Mar 30; 16(1):35. PMID: 29602314.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  52. El-Far SW, Helmy MW, Khattab SN, Bekhit AA, Hussein AA, Elzoghby AO. Phytosomal bilayer-enveloped casein micelles for codelivery of monascus yellow pigments and resveratrol to breast cancer. Nanomedicine (Lond). 2018 03; 13(5):481-499. PMID: 29376765.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  53. Freag MS, Elzoghby AO. Protein-inorganic Nanohybrids: A Potential Symbiosis in Tissue Engineering. Curr Drug Targets. 2018; 19(16):1897-1904. PMID: 29076428.
    Citations: 1     Fields:    Translation:HumansAnimals
  54. Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, Kabary DM, Freag MS, Samaha MW, Mortada SM, Elkhodairy KA, Fang JY, Elzoghby AO. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018 01 10; 269:374-392. PMID: 29180168.
    Citations: 61     Fields:    Translation:HumansAnimals
  55. Elzoghby AO, El-Lakany SA, Helmy MW, Abu-Serie MM, Elgindy NA. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. Nanomedicine (Lond). 2017 Dec; 12(24):2785-2805. PMID: 29094642.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  56. Chen CH, Huang TH, Elzoghby AO, Wang PW, Chang CW, Fang JY. Squarticles as the nanoantidotes to sequester the overdosed antidepressant for detoxification. Int J Nanomedicine. 2017; 12:8071-8083. PMID: 29138563.
    Citations: 1     Fields:    Translation:Animals
  57. Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int J Pharm. 2017 Aug 30; 529(1-2):178-192. PMID: 28663087.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  58. Elzoghby AO, Mostafa SK, Helmy MW, ElDemellawy MA, Sheweita SA. Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy. Pharm Res. 2017 Sep; 34(9):1956-1969. PMID: 28643236.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  59. Gaber M, Medhat W, Hany M, Saher N, Fang JY, Elzoghby A. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes. J Control Release. 2017 05 28; 254:75-91. PMID: 28365294.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  60. Elzoghby A, Freag M, Mamdouh H, Elkhodairy K. Zein-based Nanocarriers as Potential Natural Alternatives for Drug and Gene Delivery: Focus on Cancer Therapy. Curr Pharm Des. 2017; 23(35):5261-5271. PMID: 28641543.
    Citations: 8     Fields:    Translation:HumansAnimals
  61. Elzoghby AO. Editorial: Polymeric Nanocarriers as Robust Platforms for Cancer Therapy. Curr Pharm Des. 2017; 23(35):5211-5212. PMID: 29110600.
    Citations: 1     Fields:    Translation:Humans
  62. Sabra S, Abdelmoneem M, Abdelwakil M, Mabrouk MT, Anwar D, Mohamed R, Khattab S, Bekhit A, Elkhodairy K, Freag M, Elzoghby A. Self-Assembled Nanocarriers Based on Amphiphilic Natural Polymers for Anti- Cancer Drug Delivery Applications. Curr Pharm Des. 2017; 23(35):5213-5229. PMID: 28552068.
    Citations: 8     Fields:    Translation:HumansAnimals
  63. Elzoghby AO, Hemasa AL, Freag MS. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging. J Control Release. 2016 12 10; 243:303-322. PMID: 27794493.
    Citations: 27     Fields:    Translation:HumansAnimals
  64. El-Lakany SA, Elzoghby AO, Elgindy NA, Hamdy DA. HPLC Methods for Quantitation of Exemestane-Luteolin and Exemestane-Resveratrol Mixtures in Nanoformulations. J Chromatogr Sci. 2016 Sep; 54(8):1282-9. PMID: 27130876.
    Citations: 1     Fields:    Translation:Humans
  65. Elzoghby AO, Abd-Elwakil MM, Abd-Elsalam K, Elsayed MT, Hashem Y, Mohamed O. Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery. Curr Pharm Des. 2016; 22(22):3305-23. PMID: 26845323.
    Citations: 13     Fields:    
  66. Elzoghby A. Editorial (Thematic Issue: Nanocarriers Based on Natural Polymers as Platforms for Drug and Gene Delivery Applications). Curr Pharm Des. 2016; 22(22):3303-4. PMID: 27165162.
    Citations: 2     Fields:    Translation:HumansAnimals
  67. Elzoghby AO, Vranic BZ, Samy WM, Elgindy NA. Swellable floating tablet based on spray-dried casein nanoparticles: Near-infrared spectral characterization and floating matrix evaluation. Int J Pharm. 2015 Aug 01; 491(1-2):113-22. PMID: 26095913.
    Citations: 6     Fields:    
  68. Elzoghby AO, Elgohary MM, Kamel NM. Implications of protein- and Peptide-based nanoparticles as potential vehicles for anticancer drugs. Adv Protein Chem Struct Biol. 2015; 98:169-221. PMID: 25819280.
    Citations: 22     Fields:    Translation:Humans
  69. Elgindy NA, Samy WA, Elzoghby AO. Casein-based micelles: a novel vector for delivery of the poorly soluble anticancer drug, flutamide? Ther Deliv. 2014 Jan; 5(1):7-9. PMID: 24341810.
    Citations: 1     Fields:    Translation:HumansAnimals
  70. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013 Dec 28; 172(3):1075-91. PMID: 24096021.
    Citations: 82     Fields:    Translation:HumansAnimals
  71. Elzoghby AO, Saad NI, Helmy MW, Samy WM, Elgindy NA. Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats. Eur J Pharm Biopharm. 2013 Nov; 85(3 Pt A):444-51. PMID: 23872177.
    Citations: 5     Fields:    Translation:Animals
  72. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model. Pharm Res. 2013 Oct; 30(10):2654-63. PMID: 23739989.
    Citations: 6     Fields:    Translation:Animals
  73. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics. Int J Nanomedicine. 2013; 8:1721-32. PMID: 23658490.
    Citations: 15     Fields:    Translation:Animals
  74. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: formulation, characterization, and in vivo pharmacokinetics. Eur J Pharm Biopharm. 2013 Aug; 84(3):487-96. PMID: 23403015.
    Citations: 8     Fields:    Translation:Animals
  75. Elzoghby AO, Samy WM, Elgindy NA. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm Res. 2013 Feb; 30(2):512-22. PMID: 23135815.
    Citations: 9     Fields:    Translation:Cells
  76. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012 Jul 10; 161(1):38-49. PMID: 22564368.
    Citations: 85     Fields:    Translation:HumansAnimals
  77. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012 Jan 30; 157(2):168-82. PMID: 21839127.
    Citations: 222     Fields:    Translation:HumansAnimals
  78. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation. Drug Dev Ind Pharm. 2011 Apr; 37(4):446-55. PMID: 21446829.
    Citations: 4     Fields:    Translation:Cells
  79. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled flutamide release. Int J Pharm. 2011 Jun 15; 411(1-2):113-20. PMID: 21457767.
    Citations: 4     Fields:    
  80. Elzoghby AO, El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011 Aug 10; 153(3):206-16. PMID: 21338636.
    Citations: 45     Fields:    Translation:HumansAnimals
  81. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. Drug Dev Ind Pharm. 2011 Jul; 37(7):754-64. PMID: 21204753.
    Citations: 6     Fields:    Translation:Humans
  82. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide. Eur J Pharm Biopharm. 2010 Feb; 74(2):397-405. PMID: 19944160.
    Citations: 11     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Elzoghby's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (236)
Co-Authors (1)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.